Probi, part of Symrise Group, has introduced its first postbiotic solution, marking a strategic expansion beyond its probiotic portfolio.

The launch of Probi’s postbiotic version of Lacticaseibacillus rhamnosus 271, Rham271h (DSM 6594) reflects accelerating demand for microbiome solutions with the possibility of creating a stronger footprint in the functional food and beverage category. 

Delivering health benefits in functional food and beverage formats presents challenges, particularly in maintaining the stability and viability of live probiotics. Postbiotics address this need by offering improved stability, broad ingredient compatibility, and greater formulation flexibility. 

Rham271h for Immune Support  

Derived from Lacticaseibacillus rhamnosus 271 (DMS 6594), the inactivated strain retains biological activity while offering enhanced stability, including pH, heat, and shelf stability in formulations, the company said. 

In-vitro studies have demonstrated that Rham271h maintains the immune-modulating properties  established in the probiotic strain, Rham271.  

Studies have shown that the postbiotic strain significantly increases the anti-inflammatory cytokine IL-10, while supporting gut barrier integrity and balanced immune responses linked to inflammation.  

“With a minimum effective daily dose of 10 billion TFU, Rham271h provides a stable and predictable alternative to live probiotics,” said Probi CEO Anita Johansen. “This makes it ideal for food and beverage applications where viability, shelf life, and formulation constraints are critical.” 

Rham271h is also non-GMO, gluten-free, Halal-certified, and included on EFSA’s Qualified Presumption of Safety (QPS) list. 

“Rham 271h represents an important addition to our portfolio,” Johansen added. “It allows us to offer our customers greater flexibility in product development, reflects Probi’s commitment to advancing innovation in microbiome science, and builds a strong scientific foundation for our strains.”